항암제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for anticancer drugs. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global anticancer drugs market from 2025 to 2032.

Key Insights:

• Anticancer Drugs Market Size (2025E): USD 164.1 Billion
• Projected Market Value (2032F): USD 312.1 Billion
• Global Market Growth Rate (CAGR 2025 to 2032): 9.60%

Anticancer Drugs Market - Report Scope:

Anticancer drugs are widely used in the treatment of various types of cancer, including breast cancer, lung cancer, and colorectal cancer, among others. These drugs are primarily used to kill or inhibit the growth of cancer cells and are categorized into chemotherapy, immunotherapy, targeted therapy, and hormone therapy. The market caters to hospitals, clinics, and oncology centers, with a growing focus on personalized medicine and immuno-oncology. Market growth is driven by the rising incidence of cancer, advancements in drug development, and increasing healthcare spending worldwide.

Market Growth Drivers:

The global anticancer drugs market is propelled by several key factors, including the rising prevalence of cancer globally, with an aging population being particularly vulnerable to cancer-related diseases. The increasing focus on precision medicine, which tailors treatment to individual genetic profiles, is enhancing the efficacy of anticancer drugs. Additionally, the expanding pipeline of novel anticancer agents, particularly in immunotherapy and targeted therapies, is driving market expansion. The approval of cutting-edge drugs such as CAR-T therapies and PD-1 inhibitors is also boosting growth. Increasing healthcare infrastructure, growing investments in research and development, and collaborations between biopharmaceutical companies and academic institutions are expected to further enhance market prospects.

Market Restraints:

Despite promising growth, the anticancer drugs market faces challenges, including the high cost of novel cancer treatments, which can limit access for patients in emerging economies. Regulatory hurdles for the approval of new anticancer drugs and the long timelines required for clinical trials pose significant obstacles to market entry. Furthermore, the potential for adverse side effects of certain treatments and the risk of resistance to cancer drugs can limit their effectiveness, affecting patient outcomes and treatment adherence.

Market Opportunities:

The anticancer drugs market presents significant opportunities driven by ongoing advancements in biotechnology and genomics. Immunotherapies, such as checkpoint inhibitors, are gaining popularity due to their potential to provide durable responses with fewer side effects compared to traditional chemotherapy. The increasing demand for targeted therapies, which focus on specific molecular targets, is expanding market potential. Personalized medicine and combination therapies are expected to become key trends in the anticancer drugs space, offering patients more tailored and effective treatment options. Strategic collaborations, mergers and acquisitions, and investments in cancer drug research are essential to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the anticancer drugs market globally?
• Which types of anticancer drugs are seeing the highest adoption, and how are they shaping treatment regimens?
• How are technological advancements and innovations reshaping the competitive landscape of the anticancer drugs market?
• Who are the key players contributing to the anticancer drugs market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global anticancer drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global anticancer drugs market, such as Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest heavily in R&D to develop next-generation drugs, including immunotherapies and targeted therapies, catering to the diverse needs of cancer patients. Collaborations with research institutions, healthcare providers, and government agencies are facilitating faster drug development and market access. Additionally, key players are focusing on expanding their global presence and enhancing drug affordability through pricing strategies and partnerships with generic drug manufacturers.

Key Companies Profiled:

• Roche Holding AG
• Bristol-Myers Squibb Company
• Novartis AG
• Merck & Co., Inc.
• Eli Lilly and Co.
• AstraZeneca PLC
• Johnson & Johnson
• Pfizer Inc.
• Amgen Inc.
• GlaxoSmithKline PLC

Anticancer Drugs Market Research Segmentation:

By Drug Type:

• Chemotherapy Drugs
• Immunotherapy Drugs
• Targeted Therapy Drugs
• Hormone Therapy Drugs
• Other Anticancer Drugs

By Application:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Blood Cancers
• Other Types of Cancer

By End-User:

• Hospitals
• Oncology Clinics
• Homecare Settings

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Market Overview
• 1.2. Market Analysis
• 1.3. PMR Analysis and Recommendations
• 1.4. Wheel of Fortune

2. Market Introduction

• 2.1. Market Definition
• 2.2. Market Taxonomy

3. Anti-Cancer Drugs Market Opportunity Analysis

• 3.1. Macro-Economic Factors
• 3.2. Opportunity Analysis

4. Market Background

• 4.1. Recent Developments
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Trends
• 4.3. Reimbursement Landscape
• 4.4. Regulatory Scenario

5. Macroeconomic Assumptions

6. Global Economic Outlook

• 6.1. Gross Domestic Product by Region & Country, 2019 - 2032
• 6.2. Disease Outlook

7. Key Inclusions

• 7.1. Epidemiology
• 7.2. Pipeline Analysis
• 7.3. Mergers and Acquisitions

8. North America Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 8.1. Introduction
• 8.2. Historical Market Value (US$ Bn) Analysis By Country, 2019 - 2024
  • 8.2.1. U.S.
  • 8.2.2. Canada
• 8.3. Market Value (US$ Bn) Forecast By Country, 2025 - 2032
• 8.4. Historical Market Value (US$ Bn) Trend Analysis By Drug Class, 2019 - 2024
  • 8.4.1. Cytotoxics
  • 8.4.2. Hormonal Therapy
  • 8.4.3. Targeted Therapy
    • 8.4.3.1. Monoclonal antibodies
    • 8.4.3.2. Small molecule inhibitors
• 8.5. Market Value (US$ Bn) Forecast By Drug Class, 2025 - 2032
• 8.6. Historical Market Value (US$ Bn) Trend Analysis By Indications, 2019 - 2024
  • 8.6.1. Prostate Cancer
  • 8.6.2. Lung Cancer
  • 8.6.3. Breast Cancer
  • 8.6.4. Melanoma
  • 8.6.5. Leukemia
  • 8.6.6. Others
• 8.7. Market Value (US$ Bn) Forecast By Indications, 2025 - 2032
• 8.8. Historical Market Value (US$ Bn) Trend Analysis By Distribution Channels, 2019 - 2024
  • 8.8.1. Hospital Pharmacies
  • 8.8.2. Retail Pharmacies
• 8.9. Market Value (US$ Bn) Forecast By Distribution Channels, 2025 - 2032
• 8.10. Market Attractiveness Analysis
  • 8.10.1. By Country
  • 8.10.2. By Drug Class
  • 8.10.3. By Indications
  • 8.10.4. By Distribution Channels
• 8.11. Key Market Participants - Intensity Mapping
• 8.12. Drivers and Restraints - Impact Analysis

9. Latin America Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 9.1. Introduction
• 9.2. Historical Market Value (US$ Bn) Trends Analysis By Country, 2019 - 2024
  • 9.2.1. Brazil
  • 9.2.2. Mexico
  • 9.2.3. Rest of Latin America
• 9.3. Market Value (US$ Bn) Forecast By Country, 2025 - 2032
• 9.4. Historical Market Value (US$ Bn) Trend Analysis By Drug Class, 2019 - 2024
  • 9.4.1. Cytotoxics
  • 9.4.2. Hormonal Therapy
  • 9.4.3. Targeted Therapy
    • 9.4.3.1. Monoclonal antibodies
    • 9.4.3.2. Small molecule inhibitors
• 9.5. Market Value (US$ Bn) Forecast By Drug Class, 2025 - 2032
• 9.6. Historical Market Value (US$ Bn) Trend Analysis By Indications, 2019 - 2024
  • 9.6.1. Prostate Cancer
  • 9.6.2. Lung Cancer
  • 9.6.3. Breast Cancer
  • 9.6.4. Melanoma
  • 9.6.5. Leukemia
  • 9.6.6. Others
• 9.7. Market Value (US$ Bn) Forecast By Indications, 2025 - 2032
• 9.8. Historical Market Value (US$ Bn) Trend Analysis By Distribution Channels, 2019 - 2024
  • 9.8.1. Hospital Pharmacies
  • 9.8.2. Retail Pharmacies
• 9.9. Market Value (US$ Bn) Forecast By Distribution Channels, 2025 - 2032
• 9.10. Market Attractiveness Analysis
  • 9.10.1. By Country
  • 9.10.2. By Drug Class
  • 9.10.3. By Indications
  • 9.10.4. By Distribution Channels
• 9.11. Key Market Participants - Intensity Mapping
• 9.12. Drivers and Restraints - Impact Analysis

10. Europe Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 10.1. Introduction
• 10.2. Historical Market Value (US$ Bn) Trend Analysis By Country, 2019 - 2024
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Russia
  • 10.2.7. Rest of Europe
• 10.3. Market Value (US$ Bn) Forecast By Country, 2025 - 2032
• 10.4. Historical Market Value (US$ Bn) Trend Analysis By Drug Class, 2019 - 2024
  • 10.4.1. Cytotoxics
  • 10.4.2. Hormonal Therapy
  • 10.4.3. Targeted Therapy
    • 10.4.3.1. Monoclonal antibodies
    • 10.4.3.2. Small molecule inhibitors
• 10.5. Market Value (US$ Bn) Forecast By Drug Class, 2025 - 2032
• 10.6. Historical Market Value (US$ Bn) Trend Analysis By Indications, 2019 - 2024
  • 10.6.1. Prostate Cancer
  • 10.6.2. Lung Cancer
  • 10.6.3. Breast Cancer
  • 10.6.4. Melanoma
  • 10.6.5. Leukemia
  • 10.6.6. Others
• 10.7. Market Value (US$ Bn) Forecast By Indications, 2025 - 2032
• 10.8. Historical Market Value (US$ Bn) Trend Analysis By Distribution Channels, 2019 - 2024
  • 10.8.1. Hospital Pharmacies
  • 10.8.2. Retail Pharmacies
• 10.9. Market Value (US$ Bn) Forecast By Distribution Channels, 2025 - 2032
• 10.10. Market Attractiveness Analysis
  • 10.10.1. By Country
  • 10.10.2. By Drug Class
  • 10.10.3. By Indications
  • 10.10.4. By Distribution Channels
• 10.11. Key Market Participants - Intensity Mapping
• 10.12. Drivers and Restraints - Impact Analysis

11. Asia Pacific Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 11.1. Introduction
• 11.2. Historical Market Value (US$ Bn) Trend Analysis By Country, 2019 - 2024
  • 11.2.1. China
  • 11.2.2. India
  • 11.2.3. Australia and NZ
  • 11.2.4. ASEAN
  • 11.2.5. Rest of Asia Pacific
• 11.3. Market Value (US$ Bn) Forecast By Country, 2025 - 2032
• 11.4. Historical Market Value (US$ Bn) Trend Analysis By Drug Class, 2019 - 2024
  • 11.4.1. Cytotoxics
  • 11.4.2. Hormonal Therapy
  • 11.4.3. Targeted Therapy
    • 11.4.3.1. Monoclonal antibodies
    • 11.4.3.2. Small molecule inhibitors
• 11.5. Market Value (US$ Bn) Forecast By Drug Class, 2025 - 2032
• 11.6. Historical Market Value (US$ Bn) Trend Analysis By Indications, 2019 - 2024
  • 11.6.1. Prostate Cancer
  • 11.6.2. Lung Cancer
  • 11.6.3. Breast Cancer
  • 11.6.4. Melanoma
  • 11.6.5. Leukemia
  • 11.6.6. Others
• 11.7. Market Value (US$ Bn) Forecast By Indications, 2025 - 2032
• 11.8. Historical Market Value (US$ Bn) Trend Analysis By Distribution Channels, 2019 - 2024
  • 11.8.1. Hospital Pharmacies
  • 11.8.2. Retail Pharmacies
• 11.9. Market Value (US$ Bn) Forecast By Distribution Channels, 2025 - 2032
• 11.10. Market Attractiveness Analysis
  • 11.10.1. By Country
  • 11.10.2. By Drug Class
  • 11.10.3. By Indications
  • 11.10.4. By Distribution Channels
• 11.11. Key Market Participants - Intensity Mapping
• 11.12. Drivers and Restraints - Impact Analysis

12. Japan Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 12.1. Introduction
• 12.2. Historical Market Value (US$ Bn) Trend Analysis By Drug Class, 2019 - 2024
  • 12.2.1. Cytotoxics
  • 12.2.2. Hormonal Therapy
  • 12.2.3. Targeted Therapy
    • 12.2.3.1. Monoclonal antibodies
    • 12.2.3.2. Small molecule inhibitors
• 12.3. Market Value (US$ Bn) Forecast By Drug Class, 2025 - 2032
• 12.4. Historical Market Value (US$ Bn) Trend Analysis By Indications, 2019 - 2024
  • 12.4.1. Prostate Cancer
  • 12.4.2. Lung Cancer
  • 12.4.3. Breast Cancer
  • 12.4.4. Melanoma
  • 12.4.5. Leukemia
  • 12.4.6. Others
• 12.5. Market Value (US$ Bn) Forecast By Indications, 2025 - 2032
• 12.6. Historical Market Value (US$ Bn) Trend Analysis By Distribution Channels, 2019 - 2024
  • 12.6.1. Hospital Pharmacies
  • 12.6.2. Retail Pharmacies
• 12.7. Market Value (US$ Bn) Forecast By Distribution Channels, 2025 - 2032
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Drug Class
  • 12.8.2. By Indications
  • 12.8.3. By Distribution Channels
• 12.9. Key Market Participants - Intensity Mapping
• 12.10. Drivers and Restraints - Impact Analysis

13. Middle East & Africa Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 13.1. Introduction
• 13.2. Historical Market Value (US$ Bn) Trend Analysis By Country, 2019 - 2024
  • 13.2.1. South Africa
  • 13.2.2. GCC Countries
  • 13.2.3. Rest of MEA
• 13.3. Market Value (US$ Bn) Forecast By Country, 2025 - 2032
• 13.4. Historical Market Value (US$ Bn) Trend Analysis By Drug Class, 2019 - 2024
  • 13.4.1. Cytotoxics
  • 13.4.2. Hormonal Therapy
  • 13.4.3. Targeted Therapy
    • 13.4.3.1. Monoclonal antibodies
    • 13.4.3.2. Small molecule inhibitors
• 13.5. Market Value (US$ Bn) Forecast By Drug Class, 2025 - 2032
• 13.6. Historical Market Value (US$ Bn) Trend Analysis By Indications, 2019 - 2024
  • 13.6.1. Prostate Cancer
  • 13.6.2. Lung Cancer
  • 13.6.3. Breast Cancer
  • 13.6.4. Melanoma
  • 13.6.5. Leukemia
  • 13.6.6. Others
• 13.7. Market Value (US$ Bn) Forecast By Indications, 2025 - 2032
• 13.8. Historical Market Value (US$ Bn) Trend Analysis By Distribution Channels, 2019 - 2024
  • 13.8.1. Hospital Pharmacies
  • 13.8.2. Retail Pharmacies
• 13.9. Market Value (US$ Bn) Forecast By Distribution Channels, 2025 - 2032
• 13.10. Market Attractiveness Analysis
  • 13.10.1. By Country
  • 13.10.2. By Drug Class
  • 13.10.3. By Indications
  • 13.10.4. By Distribution Channels
• 13.11. Key Market Participants - Intensity Mapping
• 13.12. Drivers and Restraints - Impact Analysis

14. Forecast Factors: Relevance and Impact

15. Forecast Assumptions

16. Competition Analysis

• 16.1. Competition Dashboard
• 16.2. Company Deep Dive
  • 16.2.1. F. Hoffmann-La Roche Ltd
    • 16.2.1.1. Overview
    • 16.2.1.2. Product and Indications Portfolio
    • 16.2.1.3. Production Footprint
    • 16.2.1.4. Sales Footprint
    • 16.2.1.5. Channel Footprint
    • 16.2.1.6. Strategy
      • 16.2.1.6.1. Marketing Strategy
      • 16.2.1.6.2. Product Strategy
      • 16.2.1.6.3. Channel Strategy
  • 16.2.2. Celgene Corp
    • 16.2.2.1. Overview
    • 16.2.2.2. Product and Indications Portfolio
    • 16.2.2.3. Production Footprint
    • 16.2.2.4. Sales Footprint
    • 16.2.2.5. Channel Footprint
    • 16.2.2.6. Strategy
      • 16.2.2.6.1. Marketing Strategy
      • 16.2.2.6.2. Product Strategy
      • 16.2.2.6.3. Channel Strategy
  • 16.2.3. Novartis AG
    • 16.2.3.1. Overview
    • 16.2.3.2. Product and Indications Portfolio
    • 16.2.3.3. Production Footprint
    • 16.2.3.4. Sales Footprint
    • 16.2.3.5. Channel Footprint
    • 16.2.3.6. Strategy
      • 16.2.3.6.1. Marketing Strategy
      • 16.2.3.6.2. Product Strategy
      • 16.2.3.6.3. Channel Strategy
  • 16.2.4. Bristol-Myers Squibb Co
    • 16.2.4.1. Overview
    • 16.2.4.2. Product and Indications Portfolio
    • 16.2.4.3. Production Footprint
    • 16.2.4.4. Sales Footprint
    • 16.2.4.5. Channel Footprint
    • 16.2.4.6. Strategy
      • 16.2.4.6.1. Marketing Strategy
      • 16.2.4.6.2. Product Strategy
      • 16.2.4.6.3. Channel Strategy
  • 16.2.5. Johnson & Johnson
    • 16.2.5.1. Overview
    • 16.2.5.2. Product and Indications Portfolio
    • 16.2.5.3. Production Footprint
    • 16.2.5.4. Sales Footprint
    • 16.2.5.5. Channel Footprint
    • 16.2.5.6. Strategy
      • 16.2.5.6.1. Marketing Strategy
      • 16.2.5.6.2. Product Strategy
      • 16.2.5.6.3. Channel Strategy
  • 16.2.6. Merck & Co.
    • 16.2.6.1. Overview
    • 16.2.6.2. Product and Indications Portfolio
    • 16.2.6.3. Production Footprint
    • 16.2.6.4. Sales Footprint
    • 16.2.6.5. Channel Footprint
    • 16.2.6.6. Strategy
      • 16.2.6.6.1. Marketing Strategy
      • 16.2.6.6.2. Product Strategy
      • 16.2.6.6.3. Channel Strategy
  • 16.2.7. Eli Lilly and Company
    • 16.2.7.1. Overview
    • 16.2.7.2. Product and Indications Portfolio
    • 16.2.7.3. Production Footprint
    • 16.2.7.4. Sales Footprint
    • 16.2.7.5. Channel Footprint
    • 16.2.7.6. Strategy
      • 16.2.7.6.1. Marketing Strategy
      • 16.2.7.6.2. Product Strategy
      • 16.2.7.6.3. Channel Strategy
  • 16.2.8. AstraZeneca plc
    • 16.2.8.1. Overview
    • 16.2.8.2. Product and Indications Portfolio
    • 16.2.8.3. Production Footprint
    • 16.2.8.4. Sales Footprint
    • 16.2.8.5. Channel Footprint
    • 16.2.8.6. Strategy
      • 16.2.8.6.1. Marketing Strategy
      • 16.2.8.6.2. Product Strategy
      • 16.2.8.6.3. Channel Strategy
  • 16.2.9. Amgen Inc..
    • 16.2.9.1. Overview
    • 16.2.9.2. Product and Indications Portfolio
    • 16.2.9.3. Production Footprint
    • 16.2.9.4. Sales Footprint
    • 16.2.9.5. Channel Footprint
    • 16.2.9.6. Strategy
      • 16.2.9.6.1. Marketing Strategy
      • 16.2.9.6.2. Product Strategy
      • 16.2.9.6.3. Channel Strategy
  • 16.2.10. Roche Holding AG
    • 16.2.10.1. Overview
    • 16.2.10.2. Product and Indications Portfolio
    • 16.2.10.3. Production Footprint
    • 16.2.10.4. Sales Footprint
    • 16.2.10.5. Channel Footprint
    • 16.2.10.6. Strategy
      • 16.2.10.6.1. Marketing Strategy
      • 16.2.10.6.2. Product Strategy
      • 16.2.10.6.3. Channel Strategy

17. Global Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Region

• 17.1. Introduction/Key Findings
• 17.2. Historical Market Value (US$ Bn) Trend Analysis By Region, 2019 - 2024
• 17.3. Market Value (US$ Bn) Forecast By Region, 2025 - 2032
  • 17.3.1. North America
  • 17.3.2. Latin America
  • 17.3.3. Europe
  • 17.3.4. Asia Pacific
  • 17.3.5. Middle East & Africa
  • 17.3.6. China
• 17.4. Market Attractiveness Analysis By Region

18. Global Anti-Cancer Drugs Analysis 2019 - 2024 and Forecast 2025 - 2032, By Drug Class

• 18.1. Introduction/Key Findings
• 18.2. Historical Market Value (US$ Bn) Trend Analysis By Drug Class, 2019 - 2024
  • 18.2.1. Cytotoxics
  • 18.2.2. Hormonal Therapy
  • 18.2.3. Targeted Therapy
    • 18.2.3.1. Monoclonal antibodies
    • 18.2.3.2. Small molecule inhibitors
• 18.3. Market Value (US$ Bn) Forecast By Drug Class, 2025 - 2032
• 18.4. Market Attractiveness Analysis

19. Global Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Indications

• 19.1. Introduction/Key Findings
• 19.2. Historical Market Value (US$ Bn) Trend Analysis By Indications, 2019 - 2024
  • 19.2.1. Prostate Cancer
  • 19.2.2. Lung Cancer
  • 19.2.3. Breast Cancer
  • 19.2.4. Melanoma
  • 19.2.5. Leukemia
  • 19.2.6. Others
• 19.3. Market Value (US$ Bn) Forecast By Indications, 2025 - 2032
• 19.4. Market Attractiveness Analysis By Indications

20. Global Anti-cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Distribution Channels

• 20.1. Introduction/Key Findings
• 20.2. Historical Market Value (US$ Bn) Trend Analysis By Distribution Channels, 2019 - 2024
  • 20.2.1. Hospital Pharmacies
  • 20.2.2. Retail Pharmacies
• 20.3. Market Value (US$ Bn) Forecast By Distribution Channels, 2025 - 2032
• 20.4. Market Attractiveness Analysis By Distribution Channels

21. Global Anti-Cancer Drugs Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 21.1. Market Value Share Analysis By All Segment
• 21.2. Y-o-Y Growth Analysis By All Segment
• 21.3. Absolute $ Opportunity

22. Research Methodology